These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12623202)

  • 1. Comparative study of the lubricant performance of Compritol HD5 ATO and Compritol 888 ATO: effect of polyethylene glycol behenate on lubricant capacity.
    N'Diaye A; Jannin V; Bérard V; Andrès C; Pourcelot Y
    Int J Pharm; 2003 Mar; 254(2):263-9. PubMed ID: 12623202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the lubricant performance of Compritol 888 ATO either used by blending or by hot melt coating.
    Jannin V; Bérard V; N'Diaye A; Andrès C; Pourcelot Y
    Int J Pharm; 2003 Aug; 262(1-2):39-45. PubMed ID: 12927386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals.
    Aburahma MH; Badr-Eldin SM
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1865-83. PubMed ID: 25152197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the lubricating effect of magnesium stearate and glyceryl behenate solid lipid nanoparticles in a direct compression process.
    Martínez-Acevedo L; Zambrano-Zaragoza ML; Vidal-Romero G; Mendoza-Elvira S; Quintanar-Guerrero D
    Int J Pharm; 2018 Jul; 545(1-2):170-175. PubMed ID: 29729408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compressibility of tableting materials and properties of tablets with glyceryl behenate.
    Mužíková J; Muchová S; Komersová A; Lochař V
    Acta Pharm; 2015 Mar; 65(1):91-8. PubMed ID: 25781708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the digestibility of solid lipid nanoparticles of glyceryl dibehenate produced by two techniques: Ultrasonication and spray-flash evaporation.
    Jannin V; Blas L; Chevrier S; Miolane C; Demarne F; Spitzer D
    Eur J Pharm Sci; 2018 Jan; 111():91-95. PubMed ID: 28966096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets.
    Roberts M; Vellucci D; Mostafa S; Miolane C; Marchaud D
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1068-76. PubMed ID: 22149472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method.
    Kang C; Lee JH; Kim DW; Lee BJ; Park JB
    AAPS PharmSciTech; 2018 Oct; 19(7):3067-3075. PubMed ID: 30094721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro release--in vivo microbiological and toxicological studies on ketoconazole lipid granules.
    Ozyazici M; Gokce EH; Ozer O; Ay Z; Guneri T; Ertan G; Gokce G; Metin DY; Hilmioglu S; Durmaz G; Yalcin A; Pekcetin C; Ozyurt D
    Pharm Dev Technol; 2007; 12(6):581-90. PubMed ID: 18161631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STUDY OF DUAL MATRIX TABLETS CONTAINING HYPROMELLOSE OF DIFFERENT VISCOSITY DEGREE AND GLYCERYL DIBEHENATE.
    Mužíková J; Holubová K; Komersová A; Lochar V
    Acta Pol Pharm; 2016; 73(2):461-8. PubMed ID: 27180439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing a wet granulation process to obtain high-dose sustained-release tablets with Compritol 888 ATO.
    Rosiaux Y; Girard JM; Desvignes F; Miolane C; Marchaud D
    Drug Dev Ind Pharm; 2015; 41(10):1738-44. PubMed ID: 25652358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pH, buffer capacity and ionic strength on quetiapine fumarate release from matrix tablets prepared using two different polymeric blends.
    Hamed R; AlJanabi R; Sunoqrot S; Abbas A
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1330-1342. PubMed ID: 28402145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of some lubricants and evaluation of compression parameters on directly compressible powders.
    Uğurlu T; Halaçoğlu MD
    Pharm Dev Technol; 2014 May; 19(3):347-54. PubMed ID: 23590449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
    Jannin V; Rosiaux Y; Doucet J
    J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices.
    Rao M; Ranpise A; Borate S; Thanki K
    AAPS PharmSciTech; 2009; 10(2):355-60. PubMed ID: 19333763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium.
    Roberts M; Pulcini L; Mostafa S; Cuppok-Rosiaux Y; Marchaud D
    Pharm Dev Technol; 2015 Jun; 20(4):507-12. PubMed ID: 24354893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hot-melt coating technology. I. Influence of Compritol 888 Ato and granule size on theophylline release.
    Faham A; Prinderre P; Farah N; Eichler KD; Kalantzis G; Joachim J
    Drug Dev Ind Pharm; 2000 Feb; 26(2):167-76. PubMed ID: 10697753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design.
    Patel JK; Patel NV; Shah SH
    Res Pharm Sci; 2009 Jul; 4(2):63-75. PubMed ID: 21589801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot melt coating technology: influence of Compritol 888 Ato and granule size on chloroquine release.
    Faham A; Prinderre P; Piccerelle P; Farah N; Joachim J
    Pharmazie; 2000 Jun; 55(6):444-8. PubMed ID: 10907253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.